Douglas K Monoline Partners... Net Worth

The estimated Net Worth of Douglas K Monoline Partners... is at least $817 Thousand dollars as of 24 July 2018. Douglas Partners owns over 165,000 units of Aquestive Therapeutics Inc stock worth over $816,750 and over the last 6 years Douglas sold AQST stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Douglas Partners AQST stock SEC Form 4 insiders trading

Douglas has made over 1 trades of the Aquestive Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Douglas bought 165,000 units of AQST stock worth $2,475,000 on 24 July 2018.

The largest trade Douglas's ever made was buying 165,000 units of Aquestive Therapeutics Inc stock on 24 July 2018 worth over $2,475,000. On average, Douglas trades about 165,000 units every 0 days since 2018. As of 24 July 2018 Douglas still owns at least 165,000 units of Aquestive Therapeutics Inc stock.

You can see the complete history of Douglas Partners stock trades at the bottom of the page.

What's Douglas Partners's mailing address?

Douglas's mailing address filed with the SEC is 201 Main St, Salinas, CA 93901, USA.

Insiders trading at Aquestive Therapeutics Inc

Over the last 6 years, insiders at Aquestive Therapeutics Inc have traded over $1,898,648 worth of Aquestive Therapeutics Inc stock and bought 370,463 units worth $3,088,399 . The most active insiders traders include Marco Taglietti, Nancy Lurker, and Alexander Mark Schobel. On average, Aquestive Therapeutics Inc executives and independent directors trade stock every 36 days with the average trade being worth of $77,928. The most recent stock trade was executed by Alexander Mark Schobel on 15 March 2024, trading 50,000 units of AQST stock currently worth $300,000.

What does Aquestive Therapeutics Inc do?

aquestive therapeutics is a specialty pharmaceutical company that advances and commercializes medicines to solve critical healthcare problems and meaningfully improve people’s lives. our team asks questions and identifies issues others have not, and builds solutions that empower patients and their caregivers with better ways to manage complex diseases. our initial focus, supported by our current approved products and late stage pipeline, is to address immediate cns challenges.

Complete history of Douglas Partners stock trades at Aquestive Therapeutics Inc

Aquestive Therapeutics Inc executives and stock owners

Aquestive Therapeutics Inc executives and other stock owners filed with the SEC include:

• A. Mark Schobel,
  Chief Innovation and Technology Officer
• Keith Kendall,
  President, Chief Executive Officer, Director
• Daniel Barber,
  Chief Operating Officer, Senior Vice President
• John Maxwell,
  Senior Vice President, Chief Financial Officer
• Keith J. Kendall,
  CEO, Pres & Director
• Daniel Barber,
  Sr. VP & COO
• Santo Costa,
  Independent Chairman of the Board
• James Scibetta,
  Independent Director
• Douglas Bratton,
  Independent Director
• Nancy Lurker,
  Independent Director
• Gregory Brown,
  Independent Director
• John Cochran,
  Vice Chairman of the Board
• Gary Slatko,
  Senior Vice President, Chief Medical Officer
• Kenneth Marshall,
  Senior Vice President - Chief Commercial Officer
• Peter Boyd,
  Senior Vice President - Business Process and Information Technology
• Theresa Wood,
  Senior Vice President - Human Resources and Organizational Development
• Lori Braender,
  Senior Vice President - General Counsel, Chief Compliance Officer and Corporate Secretary
• Dr. Gary H. Slatko M.D., MBA,
  Sr. VP & Chief Medical Officer
• Kenneth W. Marshall,
  Sr. VP & Chief Commercial Officer
• Peter E. Boyd,
  Sr. VP of Bus. Process & Information Technology
• Dr. Eric Dadey Ph.D.,
  Sr. Vice-Pres of R&D
• Theresa Wood,
  Sr. VP of HR & Organizational Devel.
• Lori J. Braender Esq.,
  Sr. VP, Gen. Counsel, Chief Compliance Officer & Corp. Sec.
• Alexander Mark Schobel,
  Chief Innovation & Technology Officer
• A. Ernest Toth Jr.,
  Sr. VP & CFO
• Timothy E Morris,
  
• Ken W. Marshall,
  SVP, Chief Commercial Officer
• Marco Taglietti,
  
• Julie Krop,
  
• Douglas K Monoline Partners...,
  
• Cassie Jung,
  SVP, Operations
• Douglas K Mono Line Partner...,
  
• Kenneth Truitt,
  Chief Medical Officer
• A Ernest Jr Toth,
  SVP, Chief Financial Officer
• Carl N Kraus,
  Chief Medical Officer
• Stephen Wargacki,
  Chief Science Officer
• Abigail L. Jenkins,
  
• Sherry Korczynski,
  SVP Sales and Marketing